Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

N-Power Medicine and New York Cancer & Blood Specialists partner to reduce size of oncology clinical trials and accelerate new therapies

N-Power Medicine and New York Cancer & Blood Specialists announced a strategic partnership to accelerate the generation of N-Power’s Prospective External Control Arms. This approach is designed to reduce the size of oncology clinical trials and bring new therapies to patients years sooner.

October 16, 2026

Vol.52 No.38

Perspective

Oncology has a semantics problem: How do we define “early stage”?

I recently found myself asking a question that I thought had an obvious answer: What is early-stage cancer?

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

NIH has introduced Linked Discoveries, an experimental tool designed to help scientists more easily see how an individual research finding relates to the larger body of biomedical evidence.

October 02, 2026

Vol.52 No.36

In Brief

ARPA-H launches SURPASS program to accelerate clinical trials

ARPA-H launched the Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS) program, together with three complementary projects, aimed at removing barriers that slow clinical development and help promising treatments reach patients sooner.

October 02, 2026

Vol.52 No.36

Clinical Roundup

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.

October 02, 2026

Vol.52 No.36

Clinical Roundup

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Researchers at the Icahn School of Medicine at Mount Sinai have identified biological mechanisms that may contribute to CAR T-cell-associated enterocolitis, a serious inflammatory condition of the intestine that can occur after a type of CAR T cell therapy for multiple myeloma.

October 02, 2026

Vol.52 No.36

Nektar Therapeutics announces NKTR-255 enhanced complete response rates in r/r LBCL

YOU MAY BE INTERESTED IN

N-Power Medicine and New York Cancer & Blood Specialists partner to reduce size of oncology clinical trials and accelerate new therapies

Oncology has a semantics problem: How do we define “early stage”?

NIH introduces “Linked Discoveries,” a PubMed tool aimed at strengthening research replication, reproducibility

ARPA-H launches SURPASS program to accelerate clinical trials

City of Hope’s “plug-and-play” CAR T platform lets researchers update cells after infusion

Mount Sinai-led study identifies why some patients develop severe intestinal inflammation after CAR T therapy

Renew today!

Subscriber content

Never miss an issue!

Login